Skip to main content

Biogen EMPAVELI revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

EMPAVELI revenue at Biogen came to $51.5M for the quarter to 30 Sep 2026.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$0Jun 2023$0Sep 2023$0Mar 2024$800,000Jun 2024$200,000Sep 2024$100,000Mar 2025$0Jun 2025$0Sep 2025$0Mar 2026$30.4MJun 2026$51.5MSep 2026
Biogen EMPAVELI revenue, every reported period
Period endingEMPAVELI revenueChange on a yearFiled
30 Sep 2026$51.5M—28 Oct 2026
30 Jun 2026$30.4M—29 Jul 2026
31 Mar 2026$0down 100.0%29 Apr 2026
30 Sep 2025$0down 100.0%30 Oct 2025
30 Jun 2025$0down 100.0%31 Jul 2025
31 Mar 2025$100,000—1 May 2025
30 Sep 2024$200,000—30 Oct 2024
30 Jun 2024$800,000—1 Aug 2024
31 Mar 2024$0—24 Apr 2024
30 Sep 2023$0—8 Nov 2023
30 Jun 2023$0—25 Jul 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · IMRALDI revenue · QALSODY revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.